---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-200078"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:00:39.917394+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned

## Summary
- 2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.
- 1L monotherapy (300 mg): ORR 47%, DCR 89% among 38 evaluable patients as of July 28, 2025 cutoff.
- 1L combo daraxonrasib 200 mg + gemcitabine/nab-paclitaxel: ORR 55%, DCR 90% in 31 evaluable patients.
- Grade ≥3 TRAEs: 34% monotherapy (2L), 35% (1L), 58% combo; most common rash, GI; 0% discontinuation in 2L.
- Company plans to initiate RASolute 303, a global Phase 3 trial in 1L PDAC comparing daraxonrasib ± GnP vs GnP.

## SEC filing metadata
- accession: 0001193125-25-200078
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312525200078/0001193125-25-200078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312525200078/d947102d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-200078
- JSON: https://secwatch.observer/filing/0001193125-25-200078.json
- Plain text: https://secwatch.observer/filing/0001193125-25-200078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.